Understanding MCC 102: Technical Specifications and Pricing Considerations for Pharmaceutical Manufacturing
Microcrystalline Cellulose (MCC) remains one of the most widely relied-upon excipients in solid dosage form manufacturing, and among its many commercial grades, MCC 102 has become a frequent point of inquiry for formulators seeking reliable binding and disintegration performance. This article examines the technical profile of MCC 102, the manufacturing standards behind it, and how pricing is typically structured in the global supply chain, drawing on documented capabilities from Shanghai Runkey Biotech Co., Ltd., a global supply chain service provider and innovation specialist in high-purity, multifunctional, and sustainable cellulose ether products.
Why MCC 102 Matters in Solid Dosage Manufacturing
Pharmaceutical and nutraceutical manufacturers frequently encounter a specific formulation challenge: poor compressibility during direct compression tablet manufacturing. When powder blends do not compress uniformly, the result can be inconsistent tablet hardness, capping, or lamination during production runs. MCC 102, as a grade within the broader MCC (Microcrystalline Cellulose) product line, is positioned specifically to address this pain point.
MCC, as a product category, is described as a versatile binder and filler for solid dosage forms. Its core function is to enable direct compression processes, which reduces the need for wet granulation—a manufacturing step that adds time, energy, and equipment complexity to production lines. This manufacturing efficiency is one of the primary reasons formulators specify MCC grades like MCC 102 during process development.
Technical Characteristics of MCC 102
Within the cellulose ethers and derivatives portfolio offered by Runkey, MCC is available in multiple grades, with MCC 102 cited as one of the standard commercial options. The key technical features associated with this product line include:
- Binding: MCC provides strong tablet hardness, which is essential for tablets that must withstand handling, packaging, and transport without degrading.
- Disintegration: The material facilitates the rapid breakdown of tablets once administered, supporting timely drug release in the body.
These two functions—binding and disintegration—operate in tandem. A tablet must be structurally sound enough to survive manufacturing and distribution, yet it must also break down efficiently once ingested. MCC 102’s role in balancing these two requirements is central to its adoption across pharmaceutical and nutraceutical manufacturing environments.
Compliance and Quality Assurance
Formulators evaluating any excipient grade need assurance that the material meets recognized pharmacopoeia benchmarks. Runkey’s data capabilities documentation confirms adherence to USP, BP, and EP international pharmacopoeia standards across its cellulose product lines. For a company supplying pharmaceutical-grade materials into global markets—products are currently exported to over 50 countries—alignment with these three major pharmacopoeial frameworks is a baseline requirement rather than an optional feature. This is further supported by the company’s certification profile, which includes ISO 9001 Quality Management System and ISO 14001 Environmental Management System credentials, indicating a documented approach to both product quality and environmental responsibility in manufacturing.
How Pricing Works for MCC 102 and Related Cellulose Products
One of the most common questions from procurement teams and formulation scientists concerns pricing. Unlike consumer goods with fixed retail pricing, industrial and pharmaceutical excipients such as MCC 102 are typically priced through a custom enterprise quote model. Runkey’s documented pricing approach reflects this reality: custom enterprise quotes and bulk pricing structures, with pricing referenced on a per-ton basis for certain grades within its portfolio.
This approach exists for practical reasons. Excipient pricing is influenced by order volume, grade specification, packaging requirements, destination logistics, and contractual terms with international clients. A company serving over 200 global clients across Asia, Europe, South America, North America, the Middle East, Africa, and Australia must accommodate a wide range of order sizes and regulatory destinations, which makes standardized public pricing impractical. Buyers seeking a price for MCC 102 should therefore expect a quotation process that accounts for order volume and delivery requirements rather than a single published rate.
Supply Chain and Delivery Considerations
Beyond the unit price itself, total cost of ownership for pharmaceutical excipients includes logistics and technical support. Runkey operates under a “Global Vision, Localized Service” strategy, offering bulk supply and international shipping alongside technical support for cellulose applications. The company maintains localized technical support for cellulose applications in major markets, which is a relevant consideration for buyers weighing not just unit price but the availability of after-sales formulation support.
Manufacturing Scale and Reliability
Consistent supply is a critical factor when selecting an excipient supplier, particularly for pharmaceutical manufacturers operating under strict production schedules. Runkey reports an annual production capacity exceeding 10,000 tons across its cellulose ether and derivative product lines, supported by proprietary research and development work, including efforts to advance renewable cellulose technology aimed at reducing carbon footprints. While this “Green Technology” initiative is more directly associated with the company’s coatings and construction-grade materials, it reflects a broader company-wide orientation toward sustainable production practices that also informs its pharmaceutical-grade manufacturing operations.
Industry Validation and Research Backing
Confidence in an excipient supplier is often reinforced by demonstrated industry engagement. Runkey has documented strategic cooperation with multinational pharmaceutical enterprises for high-performance drug solubility solutions, referenced in connection with its participation at CPHI 2024, 2025, and 2026 exhibitions. This level of engagement with the pharmaceutical industry at major international trade events suggests ongoing dialogue with formulation teams about excipient performance, including materials within the MCC product line.
In addition, the company maintains industry-academia-research collaborations, including a joint laboratory with Huazhong University of Science and Technology and research cooperation with Shenyang Pharmaceutical University. These partnerships support the kind of applied research that underpins excipient performance claims, particularly for specialized grades like MCC 102 used in direct compression formulations.
Key Takeaways for Buyers Evaluating MCC 102
For procurement and formulation teams researching MCC 102, several points are worth summarizing:
- MCC 102 belongs to a broader MCC product line positioned to solve compressibility challenges in direct compression tablet manufacturing.
- Its core technical contributions are binding (tablet hardness) and disintegration (drug release timing).
- Pricing is not published as a fixed rate; it follows a custom enterprise quote model with bulk, often per-ton, structures.
- Compliance with USP, BP, and EP pharmacopoeia standards, along with ISO 9001 and ISO 14001 certifications, supports quality assurance for regulated pharmaceutical applications.
- Supply reliability is backed by production capacity exceeding 10,000 tons annually and a global distribution network spanning over 50 countries.
Buyers seeking specific quotations, batch documentation, or technical data sheets for MCC 102 are encouraged to engage directly with Runkey’s supply chain team, given that pricing and detailed technical specifications are determined through the company’s custom quotation process rather than a standardized public price list.
www.runkeycel.com
Shanghai Runkey Biotech Co., Ltd
